Literature DB >> 22735976

Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study.

Mari Tada1, Elizabeth A Coon, Alexander P Osmand, Patricia A Kirby, Wayne Martin, Marguerite Wieler, Atsushi Shiga, Hiroe Shirasaki, Masayoshi Tada, Takao Makifuchi, Mitsunori Yamada, Akiyoshi Kakita, Masatoyo Nishizawa, Hitoshi Takahashi, Henry L Paulson.   

Abstract

We report a retrospective case series of four patients with genetically confirmed Huntington's disease (HD) and sporadic amyotrophic lateral sclerosis (ALS), examining the brain and spinal cord in two cases. Neuropathological assessment included a polyglutamine recruitment method to detect sites of active polyglutamine aggregation, and biochemical and immunohistochemical assessment of TDP-43 pathology. The clinical sequence of HD and ALS varied, with the onset of ALS occurring after the mid-50's in all cases. Neuropathologic features of HD and ALS coexisted in both cases examined pathologically: neuronal loss and gliosis in the neostriatum and upper and lower motor neurons, with Bunina bodies and ubiquitin-immunoreactive skein-like inclusions in remaining lower motor neurons. One case showed relatively early HD pathology while the other was advanced. Expanded polyglutamine-immunoreactive inclusions and TDP-43-immunoreactive inclusions were widespread in many regions of the CNS, including the motor cortex and spinal anterior horn. Although these two different proteinaceous inclusions coexisted in a small number of neurons, the two proteins did not co-localize within inclusions. The regional distribution of TDP-43-immunoreactive inclusions in the cerebral cortex partly overlapped with that of expanded polyglutamine-immunoreactive inclusions. In the one case examined by TDP-43 immunoblotting, similar TDP-43 isoforms were observed as in ALS. Our findings suggest the possibility that a rare subset of older HD patients is prone to develop features of ALS with an atypical TDP-43 distribution that resembles that of aggregated mutant huntingtin. Age-dependent neuronal dysfunction induced by mutant polyglutamine protein expression may contribute to later-life development of TDP-43 associated motor neuron disease in a small subset of patients with HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735976      PMCID: PMC3545711          DOI: 10.1007/s00401-012-1005-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Spinocerebellar ataxia type 6 with motor neuron loss: a follow-up autopsy report.

Authors:  Shinji Ohara; Teruaki Iwahashi; Takashi Oide; Ryoichi Hayashi; Takashi Nakajima; Kinya Ishikawa; Hidehiro Mizusawa
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

Review 3.  Diseases of unstable repeat expansion: mechanisms and common principles.

Authors:  Jennifer R Gatchel; Huda Y Zoghbi
Journal:  Nat Rev Genet       Date:  2005-10       Impact factor: 53.242

Review 4.  Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation.

Authors:  A Rubio; K Steinberg; D A Figlewicz; M E MacDonald; T Greenamyre; R Hamill; I Shoulson; J M Powers
Journal:  Acta Neuropathol       Date:  1996-10       Impact factor: 17.088

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

Review 6.  Pathology of CAG repeat diseases.

Authors:  M Yamada; S Tsuji; H Takahashi
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

7.  Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000.

Authors:  Yue-Shan Piao; Koichi Wakabayashi; Akiyoshi Kakita; Mitsunori Yamada; Shintaro Hayashi; Takashi Morita; Fusahiro Ikuta; Kiyomitsu Oyanagi; Hitoshi Takahashi
Journal:  Brain Pathol       Date:  2003-01       Impact factor: 6.508

8.  Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease.

Authors:  Jon Infante; José Berciano; Victor Volpini; Jordi Corral; José Miguel Polo; Julio Pascual; Onofre Combarros
Journal:  Mov Disord       Date:  2004-07       Impact factor: 10.338

Review 9.  Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).

Authors:  Sarah Furtado; Haydeh Payami; Paul J Lockhart; Melissa Hanson; John G Nutt; Andrew A Singleton; Amanda Singleton; Jamel Bower; Ryan J Utti; Thomas D Bird; Raul de la Fuente-Fernandez; Yoshio Tsuboi; Mary L Klimek; Oksana Suchowersky; John Hardy; Donald B Calne; Zbigniew K Wszolek; Matthew Farrer; Katrina Gwinn-Hardy; A Jon Stoessl
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

10.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

View more
  15 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Amyotrophic lateral sclerosis in a patient with a family history of huntington disease: genetic counseling challenges.

Authors:  Andrea L Smith; James W Teener; Brian C Callaghan; Jack Harrington; Wendy R Uhlmann
Journal:  J Genet Couns       Date:  2014-04-26       Impact factor: 2.537

Review 3.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

4.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

5.  Huntington's disease with comorbid myasthenia gravis: a case report.

Authors:  S Chatzikonstantinou; I Dagklis; D Kazis; E Karantali; S Bostantjopoulou
Journal:  Hippokratia       Date:  2019 Jan-Mar       Impact factor: 0.471

6.  Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models.

Authors:  Laurent Coudert; Takashi Nonaka; Emilien Bernard; Masato Hasegawa; Laurent Schaeffer; Pascal Leblanc
Journal:  Cell Mol Life Sci       Date:  2019-03-12       Impact factor: 9.261

7.  Amyotrophic lateral sclerosis is over-represented in two Huntington's disease brain bank cohorts: further evidence to support genetic pleiotropy of pathogenic HTT gene expansion.

Authors:  Richard A Hickman; Ramita Dewan; Etty Cortes; Bryan J Traynor; Karen Marder; Jean-Paul Vonsattel
Journal:  Acta Neuropathol       Date:  2021-11-20       Impact factor: 17.088

Review 8.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

Review 9.  Molecular, functional, and pathological aspects of TDP-43 fragmentation.

Authors:  Deepak Chhangani; Alfonso Martín-Peña; Diego E Rincon-Limas
Journal:  iScience       Date:  2021-04-21

10.  Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.

Authors:  Ramita Dewan; Ruth Chia; Jinhui Ding; Richard A Hickman; Thor D Stein; Yevgeniya Abramzon; Sarah Ahmed; Marya S Sabir; Makayla K Portley; Arianna Tucci; Kristina Ibáñez; F N U Shankaracharya; Pamela Keagle; Giacomina Rossi; Paola Caroppo; Fabrizio Tagliavini; Maria L Waldo; Per M Johansson; Christer F Nilsson; James B Rowe; Luisa Benussi; Giuliano Binetti; Roberta Ghidoni; Edwin Jabbari; Coralie Viollet; Jonathan D Glass; Andrew B Singleton; Vincenzo Silani; Owen A Ross; Mina Ryten; Ali Torkamani; Toshiko Tanaka; Luigi Ferrucci; Susan M Resnick; Stuart Pickering-Brown; Christopher B Brady; Neil Kowal; John A Hardy; Vivianna Van Deerlin; Jean Paul Vonsattel; Matthew B Harms; Huw R Morris; Raffaele Ferrari; John E Landers; Adriano Chiò; J Raphael Gibbs; Clifton L Dalgard; Sonja W Scholz; Bryan J Traynor
Journal:  Neuron       Date:  2020-11-26       Impact factor: 18.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.